Abstract
Continuous positive airway pressure (CPAP) therapy has been the gold standard therapy for moderate‐to‐severe obstructive sleep apnoea (OSA) for several decades.1 Therapeutic success for CPAP therapy is generally defined as a reduction in the apnoea–hypopnoea index (AHI) to below 5 events/h with concurrent improvement in symptoms (including daytime sleepiness, snoring and quality of life) and satisfactory long‐term adherence. This is achievable in many patients, yet approximately 50% of patients either refuse CPAP therapy or are non‐adherent.2 Others are compliant with therapy but persistently demonstrate a residual AHI ≥5 events/h indicating suboptimal control. To date, there has been limited epidemiological or mechanistic research regarding patients with a residual AHI ≥5 events/h on CPAP therapy.
Original language | English |
---|---|
Pages (from-to) | 51-52 |
Number of pages | 2 |
Journal | Respirology |
Volume | 25 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Jan 2020 |
Keywords
- continuous positive airway pressure
- residual apnoeic events
- sleep apnoea